AVIR
Atea Pharmaceuticals, Inc. Common Stock
Nasdaq · usd
Atea Pharmaceuticals, Inc. Common Stock (AVIR) trades at $3.98 (+1.27%) as of 2:25:56 PM EST on Nov 20, 2026, -1.73% over the past month. Market cap is $315.6M, with 9.6 days to cover in short interest.
Stock performance
How Atea Pharmaceuticals, Inc. Common Stock (AVIR) stock has performed from one day to one year, with its 52-week range.
- 1D
- +1.27%
- 1W
- -7.44%
- 1M
- -1.73%
- YTD
- +11.48%
- 1Y
- +34.01%
- 52-wk range
- $2.93 – $6.45
Key statistics
Today's trading snapshot for AVIR: day range, open, previous close, volume and market cap.
- Day range
- $3.80 – $4.01
- Open
- $3.88
- Prev close
- $3.93
- Volume
- 168.62K
- Market cap
- $315.6M
- Shares out
- 80.3M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Atea Pharmaceuticals, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 1.80
- P/FCF
- —
- ROE
- -88.5%
- ROA
- -77.4%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 19, 2026
8-K filings
Material corporate events Atea Pharmaceuticals, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 9, 2026
On November 9, 2026, Atea Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended September 30, 2026.
- Credit facilityNov 9, 2026
On November 6, 2026 (the "Closing Date"), Atea Pharmaceuticals, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc., as agent, and the lenders party thereto, providing for term loans in an aggregate principal amount of up to $200.0 million. The Agreement provides for senior secured term loans maturing on November 1, 2031.
- Preliminary resultsJan 8, 2026
On January 8, 2026, Atea Pharmaceuticals, Inc. (the "Company") issued a press release announcing, among other things, the Company's preliminary unaudited cash and investment balance as of December 31, 2025.
- Annual meeting resultsJun 20, 2025
On June 20, 2025, Atea Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders. Based upon the foregoing votes, Bruno Lucidi, Dr. Polly Murphy and Dr. Bruce Polsky were elected as Class II directors and Proposals 2 and 3 were approved.
- Director departureApr 17, 2025
Franklin Berger will not stand for reelection to the Board as a Class I director when his term expires at the Company's 2027 annual meeting of stockholders. Franklin Berger informed the Board that he would retire following the end of his current term as a Class I director at the 2027 Annual Meeting.
Dividend history and stock splits
Atea Pharmaceuticals, Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-11Feb 14, 2018
AVIR short interest
How heavily AVIR is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 9.6
- Short interest
- 3.01M
- Avg volume
- 315.09K
As of · reported to FINRA twice monthly.
AVIR news
The latest news and headlines about Atea Pharmaceuticals, Inc. Common Stock (AVIR).
- Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026positiveGlobeNewswire Inc.· May 27, 2026
- Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026positiveGlobeNewswire Inc.· Feb 24, 2026
- Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025positiveGlobeNewswire Inc.· Nov 7, 2025
- Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025neutralGlobeNewswire Inc.· Nov 5, 2025
- Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025neutralGlobeNewswire Inc.· Jul 31, 2025
Frequently asked questions
What is the Atea Pharmaceuticals, Inc. Common Stock (AVIR) stock price today?
Atea Pharmaceuticals, Inc. Common Stock (AVIR) is trading at $3.98 (+1.27% on the day) as of 2:25:56 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Atea Pharmaceuticals, Inc. Common Stock?
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases.
What is the short interest in AVIR?
As of Oct 30, 2026, AVIR has 3.01M shares short and 9.6 days to cover.
What exchange is AVIR listed on?
Atea Pharmaceuticals, Inc. Common Stock (AVIR) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of AVIR with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a AVIR analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.